Despite large-scale government demand for new vaccines in the past decade, few have materialized. Vaccine innovation has been falling since World War II. Hoyt’s timely investigation asks why, and teaches lessons for our efforts to rebuild biodefense capabilities when the financial payback for a vaccine is low but the social returns are high.